.svg){kind=small}
Dr Jorg Taubel will be presenting his latest scientific poster presentation on Day 1 from 14h20 to 15h00; Investigating the effect of intravenous APD421 (Amilsulpride) and the ethnic differences between Japanese and Caucasians on cardiac conductionThe theme of this year’s meeting is "Rolling back the frontiers of clinical pharmacology and therapeutics," and its focus will be to revive the spirit of the Society’s founding days and push back the horizons of new clinical pharmacology (and therapeutics) in the 21st century.
-min.jpg)
.jpg)
Latest news
Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read moreA first of a kind trial in the fight against malaria
June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read moreEvents
AHA Hypertension Scientific Sessions 2024
5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event
